文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

作者信息

Prebet Thomas, Fenaux Pierre, Vey Norbert

机构信息

Smilow Cancer center at Yale New Haven Hospital, CT, USA Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France

Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie Senior, Hopital Saint Louis, Paris, France.

出版信息

Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.

DOI:10.3324/haematol.2016.150714
PMID:27694503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5046667/
Abstract
摘要

相似文献

[1]
Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Haematologica. 2016-10

[2]
The euphoria of hypomethylating agents in MDS and AML: is it justified?

Best Pract Res Clin Haematol. 2013-10-15

[3]
Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.

Haematologica. 2016-12

[4]
Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.

Eur J Haematol. 2015-6

[5]
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

Leuk Res. 2015-5

[6]
Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.

Epigenomics. 2021-7

[7]
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Clin Lymphoma Myeloma Leuk. 2015-1

[8]
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.

Clin Cancer Res. 2015-12-23

[9]
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Br J Haematol. 2014-10

[10]
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Leukemia. 2015-5-6

引用本文的文献

[1]
Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4 T cells in MDS.

Blood Neoplasia. 2025-4-25

[2]
What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.

Cancers (Basel). 2023-4-12

[3]
Emerging treatment options for patients with high-risk myelodysplastic syndrome.

Ther Adv Hematol. 2020-11-11

[4]
Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).

Mediterr J Hematol Infect Dis. 2019-7-1

[5]
The MDS genomics-prognosis symbiosis.

Hematology Am Soc Hematol Educ Program. 2018-11-30

[6]
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Blood Cancer J. 2017-12-14

[7]
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Clin Cancer Res. 2017-9-25

本文引用的文献

[1]
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.

Haematologica. 2016-6

[2]
Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Haematologica. 2013-2

[3]
Revised international prognostic scoring system for myelodysplastic syndromes.

Blood. 2012-6-27

[4]
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Br J Haematol. 2012-6

[5]
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

J Clin Oncol. 2011-7-25

[6]
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Lancet Oncol. 2009-3

[7]
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Cancer. 2006-4-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索